{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:47:06Z","timestamp":1793641626848,"version":"4.5.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1053\/j.seminoncol.2011.11.009","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T18:00:05Z","timestamp":1327946405000},"page":"47-57","source":"Crossref","is-referenced-by-count":64,"title":["Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle"],"prefix":"10.1053","volume":"39","author":[{"given":"Monika","family":"Br\u00fcggemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kneba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2011.11.009_bib1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","article-title":"Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL)","volume":"14","author":"G\u00f6kbuget","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib3","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib4","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib5","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"Moricke","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib6","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib7","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.V85.6.1416.bloodjournal8561416","article-title":"Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance","volume":"85","author":"Campana","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.leu.2403263","article-title":"Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia","volume":"18","author":"Br\u00fcggemann","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000077554","article-title":"Minimal residual disease studies by flow cytometry in acute leukemia","volume":"112","author":"Campana","year":"2004","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib10","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood.V83.7.1892.1892","article-title":"Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes","volume":"83","author":"Cave","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)10295-1","article-title":"Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia","volume":"351","author":"Coustan-Smith","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib12","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cyto.b.20430","article-title":"Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible","volume":"74","author":"Dworzak","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/sj.leu.2402304","article-title":"Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data","volume":"15","author":"Gleissner","year":"2001","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3324\/haematol.2008.000414","article-title":"Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting","volume":"94","author":"Irving","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-2141.1999.01605.x","article-title":"Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction","volume":"106","author":"Mitterbauer","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib17","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1182\/blood.V89.7.2602","article-title":"Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation","volume":"89","author":"Radich","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"Van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib19","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/sj.leu.2402515","article-title":"T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis","volume":"16","author":"van der Velden","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib20","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/sj.leu.2402475","article-title":"Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR","volume":"16","author":"van der Velden","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib22","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.leu.2402736","article-title":"Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia","volume":"17","author":"Bjorklund","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib24","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJM199808273390904","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"339","author":"Cave","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib27","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood.V96.8.2691","article-title":"Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"96","author":"Coustan-Smith","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib28","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0140-6736(01)06355-3","article-title":"Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia","volume":"358","author":"Eckert","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/leu.2008.22","article-title":"Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?","volume":"22","author":"Fronkova","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2141.1998.00574.x","article-title":"Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia","volume":"100","author":"Goulden","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib31","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib32","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood.V92.11.4072","article-title":"Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia","volume":"92","author":"Knechtli","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib33","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.1998.00873.x","article-title":"Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia","volume":"102","author":"Knechtli","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.2003.03988.x","article-title":"Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction","volume":"120","author":"Lee","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib35","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1182\/blood-2003-04-1180","article-title":"Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"102","author":"Lee","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib36","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.20.4.1094","article-title":"Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia","volume":"20","author":"Mortuza","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib37","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood.V99.4.1253","article-title":"Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome","volume":"99","author":"Nyvold","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib38","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2403683","article-title":"Significant reduction of the hybrid BCR\/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia","volume":"19","author":"Pane","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib39","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2009.011221","article-title":"Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"95","author":"Ribera","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood-2002-02-0360","article-title":"Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome\/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)","volume":"101","author":"Scheuring","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib42","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/sj.leu.2402144","article-title":"Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance","volume":"15","author":"Schmiegelow","year":"2001","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/mpo.10217","article-title":"Post-induction residual disease in translocation t(12;21)-positive childhood ALL","volume":"40","author":"Seyfarth","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib44","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3324\/haematol.10965","article-title":"Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia","volume":"92","author":"Spinelli","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib45","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib46","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib47","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib48","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.leu.2403505","article-title":"TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse","volume":"18","author":"Van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-59745-418-6_7","article-title":"MRD detection in acute lymphoblastic leukemia patients using Ig\/TCR gene rearrangements as targets for real-time quantitative PCR","volume":"538","author":"Van der Velden","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib50","first-page":"700","article-title":"Time point-dependent concordance of flow cytometry and RQ-PCR in the MRD detection in childhood ALL: the experience of the AIEOP-BFM- ALL MRD study group","volume":"112","author":"Gaipa","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib51","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/sj.leu.2403444","article-title":"Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig\/TcR gene rearrangements and multicolor flow cytometric immunophenotyping","volume":"18","author":"Malec","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib52","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.leu.2403348","article-title":"Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"18","author":"Neale","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib53","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/bmt.2008.122","article-title":"B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL","volume":"42","author":"Fronkova","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib54","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.leu.2404925","article-title":"Non-specific amplification of patient-specific Ig\/\/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring","volume":"22","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib55","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/asheducation-2002.1.162","article-title":"Acute lymphoblastic leukemia","author":"Hoelzer","year":"2002","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib56","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/leu.2008.386","article-title":"Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR\/ABL-positive ALL: implications for residual disease monitoring","volume":"23","author":"Zaliova","year":"2009","journal-title":"Leukemia.l"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.leu.2404082","article-title":"Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations","volume":"20","author":"Burmeister","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib58","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/biot.200600037","article-title":"Genomic DNA of leukemic patients: target for clinical diagnosis of MLL rearrangements","volume":"1","author":"Meyer","year":"2006","journal-title":"Biotechnol J"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib59","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/leu.2009.17","article-title":"Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol","volume":"23","author":"Van der Velden","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/beha.2002.0182","article-title":"Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia","volume":"15","author":"Campana","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib61","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/sj.leu.2400732","article-title":"Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow","volume":"11","author":"Dworzak","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib62","first-page":"1245","article-title":"Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia","volume":"88","author":"Veltroni","year":"2003","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib63","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/leu.2009.93","article-title":"Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients","volume":"23","author":"Weerkamp","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib64","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1365-2141.2003.04393.x","article-title":"Determination of minimal residual disease in leukaemia patients","volume":"121","author":"Campana","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib65","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2002-01-0006","article-title":"Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib66","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/sj.leu.2403303","article-title":"CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease","volume":"18","author":"Dworzak","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib67","first-page":"1523","article-title":"Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia","volume":"9","author":"van Wering","year":"1995","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib68","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1182\/blood-2002-08-2613","article-title":"Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value","volume":"101","author":"Vidriales","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib69","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000055124","article-title":"Immunological detection of minimal residual disease in acute lymphoblastic leukemia","volume":"24","author":"Dworzak","year":"2001","journal-title":"Onkologie"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib70","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2141.2005.05401.x","article-title":"Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR","volume":"128","author":"Kerst","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib71","first-page":"1516","article-title":"Four-color flow cytometry bypasses limitations of IG\/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia","volume":"90","author":"Robillard","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib72","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.leu.2403559","article-title":"Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection","volume":"19","author":"Gaipa","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib74","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/sj.leu.2403911","article-title":"Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death","volume":"19","author":"van der Sluijs-Gelling","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2141.2000.02143.x","article-title":"Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease","volume":"110","author":"van Wering","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib76","first-page":"1697","article-title":"Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia","volume":"90","author":"Stams","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cyto.b.20516","article-title":"Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon","volume":"78","author":"Dworzak","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cyto.b.20486","article-title":"Harmonization of light scatter and fluorescence flow cytometry profiles obtained after staining peripheral blood leucocytes for cell surface-only versus intracellular antigens with the Fix & Perm reagent","volume":"78","author":"da Costa","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib79","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/cyto.a.20638","article-title":"A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders","volume":"73A","author":"Pedreira","year":"2008","journal-title":"Cytometry A"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib80","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/cyto.a.20608","article-title":"Generation of flow cytometry data files with a potentially infinite number of dimensions","volume":"73","author":"Pedreira","year":"2008","journal-title":"Cytometry A"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib81","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V95.3.790.003k48_790_794","article-title":"Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia","volume":"95","author":"Panzer-Grumayer","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib82","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2009.07941.x","article-title":"Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII\/ECOG2993","volume":"148","author":"Patel","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib83","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib84","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.hoc.2009.07.010","article-title":"Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia","volume":"23","author":"Campana","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib85","first-page":"1126","article-title":"Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor g and d gene rearrangements","volume":"87","author":"Gameiro","year":"2002","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib86","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1365-2141.2003.03974.x","article-title":"Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia","volume":"120","author":"Krampera","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib87","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"106","author":"Wassmann","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib88","first-page":"1877","article-title":"Post-remission therapy with imatinib and HAM improve MRD before tansplant for patients with philadelphia-positive acute lymphoblastic leukemia (Ph+ALL): results of the GRAALL AFR03 Study","volume":"108","author":"Leguay","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib89","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.bmt.1704241","article-title":"Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD study group","volume":"32","author":"Krejci","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib90","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/sj.leu.2402552","article-title":"Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL","volume":"16","author":"Bader","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib91","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib92","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2008.5","article-title":"Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia","volume":"22","author":"Flohr","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib93","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008","volume":"24","author":"Br\u00fcggemann","year":"2010","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2011.11.009_bib94","first-page":"S129","article-title":"Risk\/MRD adapted GMALL trials in adult ALL","volume":"83","author":"G\u00f6kbuget","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib95","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/beha.2002.0229","article-title":"Risk-adapted treatment according to minimal residual disease in adult ALL","volume":"15","author":"G\u00f6kbuget","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.009_bib96","first-page":"1872","article-title":"Treatment of High-Risk (HR) Philadelphia chromosome-negative (Ph-) adult acute lymphoblastic leukemia (ALL) according to classical risk factors and minimal residual disease (MRD)","volume":"108","author":"Ribera","year":"2006","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775411002983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775411002983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T17:18:11Z","timestamp":1713460691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775411002983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0093775411002983"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2011.11.009","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}